BSPRY

Across TCGA pan-cancer cohorts, BSPRY mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BSPRY data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BSPRY mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BSPRY expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where BSPRY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.778	0.370	.001	78	view →
HNSC	OS	Quartile	III,IV	1.000	0.762	<.001	64	view →
PDAC	DFS	Median	II,III,IV	0.538	0.299	.005	39	view →
UCEC	OS	Median	All	1.000	0.899	.005	38	view →
LUAD	DFS	Median	All	0.637	0.946	.003	13	view →
LSCC	DFS	Median	All	0.912	0.460	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BSPRY–CCRCC (DFS)

Open the CCRCC breakdown →